Mascoma Wealth Management LLC Has $120,000 Stock Position in Danaher Co. (NYSE:DHR)

Mascoma Wealth Management LLC lifted its position in Danaher Co. (NYSE:DHR) by 122.2% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 480 shares of the conglomerate’s stock after acquiring an additional 264 shares during the period. Mascoma Wealth Management LLC’s holdings in Danaher were worth $120,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in DHR. Oregon Public Employees Retirement Fund grew its holdings in shares of Danaher by 0.7% during the second quarter. Oregon Public Employees Retirement Fund now owns 56,618 shares of the conglomerate’s stock valued at $14,146,000 after buying an additional 410 shares in the last quarter. Naviter Wealth LLC increased its holdings in shares of Danaher by 7.9% in the 2nd quarter. Naviter Wealth LLC now owns 8,268 shares of the conglomerate’s stock valued at $2,068,000 after purchasing an additional 605 shares during the period. Legacy Capital Wealth Partners LLC purchased a new stake in shares of Danaher in the second quarter worth approximately $223,000. Evermay Wealth Management LLC boosted its holdings in shares of Danaher by 0.8% during the second quarter. Evermay Wealth Management LLC now owns 11,402 shares of the conglomerate’s stock worth $2,852,000 after purchasing an additional 96 shares during the period. Finally, Adell Harriman & Carpenter Inc. increased its stake in Danaher by 6.9% in the 2nd quarter. Adell Harriman & Carpenter Inc. now owns 15,854 shares of the conglomerate’s stock valued at $3,961,000 after buying an additional 1,030 shares during the period. Institutional investors and hedge funds own 79.05% of the company’s stock.

Insider Activity

In related news, CFO Matthew Mcgrew sold 16,172 shares of the firm’s stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $279.84, for a total value of $4,525,572.48. Following the completion of the transaction, the chief financial officer now directly owns 29,407 shares of the company’s stock, valued at $8,229,254.88. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other news, CFO Matthew Mcgrew sold 16,172 shares of the stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $279.84, for a total value of $4,525,572.48. Following the completion of the transaction, the chief financial officer now owns 29,407 shares in the company, valued at approximately $8,229,254.88. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CEO Rainer Blair sold 9,007 shares of Danaher stock in a transaction dated Wednesday, July 31st. The shares were sold at an average price of $280.00, for a total transaction of $2,521,960.00. Following the sale, the chief executive officer now owns 97,983 shares in the company, valued at $27,435,240. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 39,659 shares of company stock worth $11,042,433. Company insiders own 11.10% of the company’s stock.

Danaher Stock Performance

NYSE DHR opened at $264.23 on Wednesday. The company’s fifty day moving average is $260.50 and its two-hundred day moving average is $255.49. The firm has a market capitalization of $195.71 billion, a price-to-earnings ratio of 44.78, a P/E/G ratio of 4.43 and a beta of 0.83. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.43 and a quick ratio of 1.04. Danaher Co. has a 52-week low of $182.09 and a 52-week high of $281.70.

Danaher (NYSE:DHR) last released its earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share for the quarter, topping analysts’ consensus estimates of $1.57 by $0.15. The business had revenue of $5.74 billion for the quarter, compared to the consensus estimate of $5.59 billion. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The firm’s revenue for the quarter was down 2.9% compared to the same quarter last year. During the same period last year, the business earned $2.05 earnings per share. Equities research analysts forecast that Danaher Co. will post 7.59 EPS for the current year.

Wall Street Analyst Weigh In

Several research firms have recently commented on DHR. The Goldman Sachs Group boosted their price target on shares of Danaher from $225.00 to $250.00 and gave the company a “neutral” rating in a report on Wednesday, July 24th. Bank of America lifted their price target on Danaher from $270.00 to $275.00 and gave the company a “neutral” rating in a report on Wednesday, July 24th. Wells Fargo & Company began coverage on shares of Danaher in a research note on Tuesday, August 27th. They issued an “equal weight” rating and a $280.00 target price for the company. StockNews.com downgraded shares of Danaher from a “buy” rating to a “hold” rating in a research report on Tuesday, June 25th. Finally, Robert W. Baird lifted their price target on shares of Danaher from $271.00 to $278.00 and gave the company an “outperform” rating in a research report on Wednesday, July 24th. Seven research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. According to data from MarketBeat.com, Danaher presently has an average rating of “Moderate Buy” and a consensus price target of $278.94.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.